利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.013 秒)

    INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID
    2.
    发明公开
    INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID 有权
    肾上腺皮质激素受体阻滞剂

    公开(公告)号：EP1732512A2

    公开(公告)日：2006-12-20

    申请号：EP05704917.3

    申请日：2005-01-03

    申请人： Cydex Inc.

    发明人： PIPKIN; James, D. ,  ZIMMERER, Rupert, O. ,  THOMPSON, Diane, O. ,  MOSHER, Gerold, L.

    IPC分类号： A61K9/12 ,  C08B37/16

    CPC分类号： A61K9/0078 ,  A61K9/0075 ,  A61K9/08 ,  A61K31/137 ,  A61K31/167 ,  A61K31/46 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58 ,  A61K47/40 ,  A61K47/6951 ,  B82Y5/00 ,  A61K31/16 ,  A61K2300/00 ,  A61K31/57 ,  A61K31/715

    摘要： An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.

    摘要翻译： 提供含有SAE-CD和皮质类固醇的可吸入单位剂量液体制剂。 该制剂适于用任何已知的雾化器通过雾化给予受试者。 制剂可以包含在试剂盒中。 制剂作为水溶液或浓缩组合物施用。 该制剂用于通过吸入施用皮质类固醇的改进的雾化系统。 配方中的SAE-CD显着提高了皮质类固醇（如布地奈德）的化学稳定性。 提供了通过吸入给药该制剂的方法。 制剂也可以通过常规鼻腔输送装置来施用。 通过将固体或液体（溶解）形式的SAE-CD与可吸入悬浮液的单位剂量制剂混合来制备制剂。

    USE OF SULFOALKYL ETHER CYCLODEXTRIN AS A PRESERVATIVE
    3.
    发明公开
    USE OF SULFOALKYL ETHER CYCLODEXTRIN AS A PRESERVATIVE 审中-公开
    USE磺烷基醚环糊精AS防腐剂

    公开(公告)号：EP1485110A1

    公开(公告)日：2004-12-15

    申请号：EP03723771.6

    申请日：2003-03-19

    申请人： Cydex Inc.

    发明人： MOSHER, Gerold, L. ,  PIPKIN, James, D. ,  ZIMMERER, Rupert, O. ,  FULK, CHristina, M. ,  THOMPSON, Diane, O.

    IPC分类号： A61K31/724 ,  A61K47/40

    CPC分类号： B82Y5/00 ,  A61K9/0019 ,  A61K31/05 ,  A61K31/724 ,  A61K47/40 ,  A61K47/6951 ,  Y02A50/473 ,  A61K2300/00

    摘要： An injectable formulation of a sedative hypnotic drug, such as the anesthetic drug propofol, that is pharmaceutically stable and demonstrates a reduced incidence of pain upon injection. The formulation of the present invention employs a sulfoalkyl ether cyclodextrin solubilizing and complexing excipient, such as CAPTISOL(R) cyclodextrin (sulfobutyl ether beta-cyclodextrin) to form a true aqueous solution and not a suspension. This formulation minimizes the allergic response and microbial contamination issues typically associated with propofol parenteral formulations. The present formulation may also reduce pain on injection as compared to the known emulsion type propofol formulations. The liquid formulation can be sterile filtered unlike emulsion-type formulations of sedative hypnotics. The liquid formulation can be lyophilized or otherwise dried to yield a solid formulation.

    FORMULATIONS CONTAINING PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
    5.
    发明公开
    FORMULATIONS CONTAINING PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN 审中-公开
    制剂异丙酚及甲磺烷基醚环糊精

    公开(公告)号：EP1383445A1

    公开(公告)日：2004-01-28

    申请号：EP02723536.5

    申请日：2002-03-19

    申请人： Cydex Inc.

    发明人： MOSHER, Gerold, L. ,  THOMPSON, Diane, O.

    IPC分类号： A61F2/02

    CPC分类号： B82Y5/00 ,  A61K31/05 ,  A61K31/724 ,  A61K47/6951 ,  A61K2300/00

    摘要： An injectable formulation of a sedative hypnotic drug, such as the anesthetic drug propofol, that is pharmaceutically stable and demonstrates a reduced incidence of pain upon injection. The formulation of the present invention employs a sulfoalkyl sther cyclodextrin solubilizing and complexing excipient, such as CAPTISOL® cyclodextrin (sulfobutyl ether β-cyclodextrin) to form a true aqueous solution and not a suspension. This formulation minimizes the allergic response and microbial contamination issues typically associated with propofol parenteral formulations. The present formulation may also reduce pain on injection as compared to the known emulsion type propofol formulations. The liquid formulation can be sterile filtered unlike emulsion-type formulations of sedative hypnotics. The liquid formulation can be lyophilized or otherwise dried to yield a solid formulation.

    TASTE-MASKED FORMULATIONS CONTAINING SERTRALINE AND SULFOALKYL ETHER CYCLODEXTRIN
    6.
    发明公开
    TASTE-MASKED FORMULATIONS CONTAINING SERTRALINE AND SULFOALKYL ETHER CYCLODEXTRIN 审中-公开
    TASTE HIDDEN制剂舍曲林和磺烷基醚环糊精

    公开(公告)号：EP1742535A2

    公开(公告)日：2007-01-17

    申请号：EP05804782.0

    申请日：2005-04-19

    申请人： Cydex Inc.

    发明人： MOSHER, Gerold, L. ,  GAYED, Atef, A. ,  WEDEL, Rebecca, L.

    IPC分类号： A01N43/04 ,  A61K31/715

    CPC分类号： A61K31/715 ,  A61K9/0095 ,  A61K31/137 ,  A61K31/724 ,  A61K47/40 ,  A61K47/6951 ,  B82Y5/00 ,  C08B37/0015 ,  C08L5/16

    摘要： The present invention provides aqueous oral formulations containing sertraline, or a pharmaceutically acceptable salt thereof, and a sulfoalkyl ether cyclodextrin. The liquid formulations are pleasant tasting, convenient to use, and chemically and physically stable. The liquid formulations can be administered directly or diluted before administration. Unlike the commercially available ZOLOFTTM formulation, the liquid formulations herein do not precipitate upon dilution with water, fruit juices, sodas or other pharmaceutically acceptable oral liquid carriers. The sulfoalkyl ether cyclodextrin-containing formulation provides significant advantages over the marketed non-aqueous formulation and other cyclodextrin-containing formulations of sertraline. The formulation can be self-preserved against microbial growth. The SAE-CD-containing formulation of sertraline can be provided in liquid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid formulations can be prepared. The formulation is available as a clear solution or a suspension.

    FORMULATIONS CONTAINING AMIODARONE AND SULFOALKYL ETHER CYCLODEXTRIN
    8.
    发明公开
    FORMULATIONS CONTAINING AMIODARONE AND SULFOALKYL ETHER CYCLODEXTRIN 有权
    制剂含胺碘酮磺烷基醚环糊精

    公开(公告)号：EP1501496A2

    公开(公告)日：2005-02-02

    申请号：EP03728598.8

    申请日：2003-04-29

    申请人： Cydex Inc.

    发明人： MOSHER, Gerold, L. ,  JOHNSON, Karen, T. ,  GAYED, Atef, A.

    IPC分类号： A61K31/343 ,  A61K31/724

    CPC分类号： A61K49/0006 ,  A61K9/0019 ,  A61K31/343 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/6951 ,  B82Y5/00

    摘要： The present invention provides aqueous parenteral formulations containing an antiarrhythmic agent, such as amiodarone, and a sulfoalkyl ether cyclodextrin. The liquid formulations are clear, sterilizable, and chemically and physically stable. The liquid formulations do not require a surfactant and do not precipitate upon dilution with distilled water or other pharmaceutically acceptable liquid carrier. The sulfoalkyl ether cyclodextrin-containing formulation provides significant advantages over other cyclodextrin-containing formulations of amiodarone. The formulation can be prepared in acidic, neutral and slightly basic medium while providing acceptable concentrations of amiodarone suitable for parental administration. An SAE-CD-containing formulation of amiodarone can be provided in liquid form or as a reconstitutable powder. Moreover, highly concentrated solutions exceeding 200 mg of amiodarone per mL can be prepared. Solutions can be made either dilutable or non-dilutable with water at room temperature or under conditions typically encountered in the clinic.